One-Month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy versus

Standard 12-Month Dual Antiplatelet Therapy with Clopidogrel After Drug-Eluting Stent Implantation:



<u>Hirotoshi Watanabe</u>

Takenori Domei, Takeshi Morimoto, Hiroki Shiomi, Masahiro Natsuaki, Toshiaki Toyota, Kensuke Takagi, Yoshiki Hata, Satoru Suwa, Mamoru Nanasato, Masanobu Ohya, Masahiro Yagi, Takafumi Yokomatsu, Mitsuru Abe, Kenji Ando, Kazushige Kadota, Ken Kozuma, Yoshihiro Morino, Yuji Ikari, Kengo Tanabe, Koichi Nakao, Kazuya Kawai, Yoshihisa Nakagawa, and Takeshi Kimura, on behalf of STOPDAPT-2 investigators



Background

- Mandatory 1-month DAPT had been the standard care after BMS implantation.
- DAPT duration was prolonged after introduction of DES without firm scientific evidence.
- New generation DES has substantially reduced stent thrombosis.
- Prolonged DAPT is inevitably associated with increase in bleeding.
- Bleeding is associated with subsequent mortality risk at least comparable to that of MI.
- Therefore, very short mandatory DAPT duration after DES might be an attractive option, if not associated with increase in ischemic events disproportionate to the reduction in bleeding events.




STOPDAPT

Prospective multicenter open-label single arm trial evaluating 3-month DAPT after CoCr-EES implantation

Primary Endpoint

Cardiovascular death, MI, Stroke, Definite ST, and Bleeding



Cardiovasc Interv Ther 2016; 31: 196–209.




Objective

The objective of the STOPDAPT-2 trial is to explore the safety and efficacy of the experimental regimen of 1-month DAPT followed by clopidogrel monotherapy as compared with the standard 12-month DAPT with aspirin and clopidogrel after implantation of cobalt-chromium everolimus-eluting stents (CoCr-EES).



STOPDAPT-2:

Prospective multicenter open-label randomized trial comparing 1-month versus 12-month DAPT after CoCr-EES implantation with limited exclusion criteria.





Study Organization

Steering Committee

Takeshi Kimura (PI) Kazushige Kadota Ken Kozuma Yoshihiro Morino Keiichi Igarashi-Hanaoka Yuji Ikari Kengo Tanabe Kenji Ando Koichi Nakao Kazuya Kawai Mitsuru Abe

Trial Statistician

Takeshi Morimoto

Clinical Event Committee

Yoshihisa Nakagawa Yutaka Furukawa Masahiro Natsuaki Hiroki Shiomi Toshiaki Toyota

Safety Evaluation Committee

Shunichi Miyazaki Ryuji Nohara

Coordinating Center

Research Institute for Production Development, Kyoto, Japan Saori Tezuka Yumika Fujino

Angiography Core Laboratory

Cardio Core Japan, Tokyo, Japan

Study administrative staff

Masahiro Natsuaki Hirotoshi Watanabe Toshiaki Toyota Toshikazu Jinnai

Funded by

Abbott Vascular Japan, Co., Ltd.



90 Participating Centers

Teine Keijinkai Hospital Hokko Memorial Hospital Hirosaki University Hospital Iwate Medical University Hospital Sendai Kousei Hospital Sendai Cardiovascular Center Tohoku Medical and Pharmaceutical University Hospital Nakadori General Hospital Nihonkai General Hospital Hoshi General Hospital Jichi Medical University Hospital Mashiko Hospital Mitsui Memorial Hospital Juntendo University Hospital The Fraternity Memorial Hospital Edogawa Hospital Showa University Koto Toyosu Hospital Tokyo Women's Medical University Hospital Tokyo General Hospital Juntendo University Nerima Hospital Kawakita General Hospital Sakakibara Heart Institute Tokyo Metropolitan Tama Medical Center Minamino Cardiovascular Hospital Higashiyamato Hospital St. Marianna University School of Medicine Hospital Yokohama Rosai Hospital Showa University Fujigaoka Hospital Saiseikai Yokohamashi Tobu Hospital Yokohama City University Medical Center

Kitasato University Hospital Hiratsuka Kvosai Hospital Tokai University Hospital Kimitsu Chuo Hospital Kanazawa Cardiovascular Hospital University of Fukui Hospital Municipal Tsuruga Hospital University of Yamanashi Hospital Gifu Prefectural General Medical Center Ogaki Municipal Hospital Juntendo University Shizuoka Hospital Shizuoka General Hospital Japanese Red Cross Nagova Daini Hospital Handa City Hospital Tosei General Hospital Ichinomiyanishi Hospital Yokkaichi Hazu Medical Center Matsusaka Central General Hospital Nabari City Hospital Otsu Red Cross Hospital Hikone Municipal Hospital Kyoto University Hospital Kvoto Medical Center Mitsubishi Kyoto Hospital Kitano Hospital Osaka Red Cross Hospital National Cerebral and Cardiovascular Center Kindai University Hospital Mimihara General Hospital Bell Land General Hospital

Kobe City Medical Center General Hospital Kindai University Nara Hospital Tenri Hospital Japanese Red Cross Wakayama Medical Center Wakayama Medical University Hospital Shimane University Hospital Japanese Red Cross Okayama Hospital Kurashiki Central Hospital Hiroshima University Hospital Iwakuni Medical Center Tokuyama Central Hospital Shimonoseki City Hospital Tokushima University Hospital Tokushima Red Cross Hospital Kagawa Prefectural Central Hospital Ehime Prefectural Central Hospital Matsuyama Red Cross Hospital Chikamori Hospital Kokura Memorial Hospital Hospital of University of Occupational and Environmental Health Japan Saiseikai Fukuoka General Hospital Fukuoka Tokushukai Hospital Kumamoto University Hospital Saiseikai Kumamoto Hospital Japanese Red Cross Kumamoto Hospital Miyazaki Prefectural Nobeoka Hospital Ibusuki Medical Center Izumi Regional Medical Center Urasoe General Hospital Nakagami Hospital



Inclusion Criteria

- PCI with exclusive use of CoCr-EES (Xience[™] series)
- No major complications during hospitalization for index PCI
- No plan for staged PCI
- Patients who could take DAPT with aspirin and P2Y₁₂ inhibitors

Key Exclusion Criteria

- Needs for oral anticoagulants
- History of intracranial hemorrhage



Endpoints

Primary endpoint:

Net adverse cardiovascular events (NACE: Ischemia and Bleeding)

 A composite of cardiovascular death, MI, Definite ST, Stroke, or TIMI major/minor bleeding

Major secondary endpoints:

Ischemic composite endpoint

- A composite of cardiovascular death, MI, Definite ST, or Stroke
 Bleeding endpoint
- TIMI major/minor bleeding



Sample Size Calculation


• Hypothesis: Non-inferiority of 1-month DAPT to 12-month DAPT

for the primary endpoint at 1-year

- Assumption: Event rate at 1-year: 4.6% (Based on RESET study).
- Non-inferiority margin; 50% on the hazard ratio scale
- Randomization ratio: 1:1
- One-sided alpha: 0.025
- Power: 85%
- Sample size: 3000 patients (1500 in each arm)




Study Flow





Participants vs Non-participants

	Participants N=3009	Non-participants N=3287	P value
Age, y	68.6±10.7	70.0 ± 11.7	<0.001
ACS	38%	39%	0.61
STEMI	19%	22%	0.003
Prior MI	14%	23%	<0.001
Prior 1st-generation DES implantation	4%	6%	<0.001
Diabetes	39%	39%	0.47
Severe CKD	6%	9%	<0.001
Dialysis	3%	5%	<0.001
Target of LMCA	3%	5%	<0.001
Two or more target vessels	7%	9%	0.003





Baseline Clinical Characteristics


	1-month DAPT N=1500	12-month DAPT N=1509
Age, years	68.1±10.9	69.1±10.4
Men	79%	77%
ACS	38%	39%
STEMI	19%	18%
Stable CAD	62%	61%
Diabetes	39%	38%
Severe CKD (eGFR<30ml/min/m ²)	6%	6%
Prior MI	14%	13%
Prior PCI	34%	35%
CREDO-Kyoto thrombotic risk score		
High; Intermediate; Low	8%; 21%; 71%	8%; 24%; 68%
CREDO-Kyoto bleeding risk score		
High; Intermediate; Low	7%; 27%; 66%	7%; 27%; 66%



STOPDAPT-2 Procedural Characteristics and Medications


	1-month DAPT N=1500	12-month DAPT N=1509
Transradial approach	82%	84%
N of target lesions	1.12 ± 0.35	1.14 ± 0.39
Minimal stent diameter, mm	2.98 ± 0.49	2.96 ± 0.48
Total stent length, mm	30.3 ± 16.7	30.5 ± 16.8
SYNTAX Score	8 (5-14)	9 (6-15)
Target of LMCA	3%	3%
СТО	4%	4%
IVUS or OCT	97%	98%
ASA	99.8%	100%
Clopidogrel	60%	63%
Prasugrel (3.75mg/day)	40%	37%
Statin	88%	87%
PPI	79%	79%

Persistent DAPT discontinuation rate




STOPPAPT-2 Primary Endpoint: Net clinical benefit

CV death/MI/ST/Stroke/TIMI major/minor bleeding






Major secondary ischemic endpoint CV death/MI/ST/Stroke




Major secondary bleeding endpoint TIMI major/minor bleeding



STOPDAPT-2






* 2 cases of probable ST (undefined death) in the 1-month DAPT group occurred before discontinuing DAPT at 1-month

STOPDAPT-2 Subgroup analysis for the primary endpoint (1)

	1-month DAPT (N=1500)	12-month DAPT (N=1509)	NI margin	HR (95%CI)	P superiority Pinte	raction
Age						
>=75 years	10/448 (2.26%)	25/499 (5.08%)	B	0.44 (0.21-0.92)	0.03	20
<75 years	25/1052 (2.41%)	30/1010 (3.02%)	₩-	0.80 (0.47-1.36)	0.41	20
ACS						
Yes	16/565 (2.88%)	23/583 (4.02%)		0.72 (0.38-1.36)	0.44	64
No	19/935 (2.05%)	32/926 (3.49%)		0.59 (0.33-1.03)	0.06	04
STEMI						
Yes	9/291 (3.15%)	14/270 (5.26%)	B	0.60 (0.26-1.38)	0.23	07
No	26/1209 (2.18%)	41/1239 (3.36%)	∎	0.65 (0.40-1.06)	0.08	87
Severe CKD						
Yes	9/82 (11.22%)	5/84 (5.97%)		1.93 (0.65-5.75)	0.24	02
No	26/1418 (1.86%)	50/1425 (3.56%)		0.52 (0.32-0.84)	0.007	03
Diabetes						
Yes	18/585 (3.12%)	25/574 (4.45%)		0.70 (0.38-1.29)	0.26	0.65
No	17/915 (1.88%)	30/935 (3.24%)		0.58 (0.32-1.05)	0.07	65
Total stent length >=28mm	1					
Yes	19/742 (2.60%)	33/787 (4.23%)	∎}	0.61 (0.35-1.07)	0.08	
No	16/758 (2.14%)	22/722 (3.12%)		0.69 (0.36-1.32)	0.26	76
Two or more target vessels						
Yes	4/100 (4.14%)	8/116 (6.94%)		0.58 (0.17-1.92)	0.37	<u>-</u>
No	31/1400 (2.24%)	47/1393 (3.43%)	-∎-	0.66 (0.42-1.03)	0.07	0.85
Overall	35/1500 (2.36%)	55/1509 (3.70%)	-	0.64 (0.42-0.98)	0.038	
	1-month	DAPT better	5 0.25 0.5 1 2 4	$\stackrel{\sim}{\rightarrow}$ 12-month D	APT better	

STOPDAPT-2 Subgroup analysis for the primary endpoint (2)





Limitations

- Lack of consensus on the use of the NACE as primary endpoint
- Open label design with its inherent limitations
- Limited enrollment of high ischemic risk patients
- Lower ischemic risk of Japanese versus US/European CAD patients
- Ticagrelor / Prasugrel (standard dose) not available in Japan
- No assessment of aspirin monotherapy after 1-month DAPT



Conclusions

One-month DAPT followed by clopidogrel monotherapy provided a net clinical benefit for ischemic and bleeding events over 12-month DAPT with aspirin and clopidogrel after CoCr-EES implantation.

The benefit was driven by significant reduction in bleeding events without increase in ischemic events.